Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | FOS | P01100 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14821479 | 0.91 | MMP2 (0.40) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL14821005 | 0.90 | MMP2 (0.39) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL14821112 | 0.90 | MMP2 (0.39) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL15946449 | 0.87 | NPC1 (0.46) | MMP2MMP3ABCB1SMN1; SMN2POLB | |
| SCHEMBL14821481 | 0.85 | ABCB1 (0.44) | ABCB1FOSJUNHTTSMN1; SMN2 | |
| SCHEMBL14821152 | 0.83 | MMP2 (0.37) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL14821495 | 0.83 | TMPRSS15 (0.42) | MMP2MMP3ABCB1PRSS1TMPRSS15 | |
| SCHEMBL14821475 | 0.82 | GAA (0.40) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL14821138 | 0.82 | PRSS1 (0.40) | MMP2MMP3ABCB1FOSJUN | |
| SCHEMBL14821756 | 0.81 | TMPRSS15 (0.43) | MMP2MMP3ABCB1FOSJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013041204-A1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | 2LUTION GmbH (DE) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | MMP2 1848/4885MMP3 1971/4885ABCB1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.